Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

517.60
+24.384.94%
Post-market: 515.10-2.5000-0.48%19:57 EDT
Volume:1.98M
Turnover:1.01B
Market Cap:55.90B
PE:13.13
High:518.27
Open:498.00
Low:494.42
Close:493.22
Loading ...

Regeneron Pharmaceuticals : Jury Awards $135.6 Mln of Compensatory Damages & $271.2 Mln in Punitive Damages for Violating Antitrust and Tort Laws

THOMSON REUTERS
·
16 May

Regeneron Wins $406.8 Million in Antitrust Lawsuit Against Amgen Over Unfair Market Practices

Reuters
·
16 May

Top Calls on Wall Street: Nvidia, AMD, Apple, Sea, Microsoft, Alibaba, UnitedHealth & More

Tiger Newspress
·
14 May

Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck. -- Barrons.com

Dow Jones
·
14 May

Regeneron Pharma Raised to Buy From Neutral by Citigroup

Dow Jones
·
14 May

Citigroup Upgrades Regeneron Pharmaceuticals to Buy From Neutral, Adjusts PT to $700 From $600

MT Newswires Live
·
14 May

Regeneron Pharmaceuticals Inc. Stock Climbs 9.1%, Outperforms Competitors

Dow Jones
·
13 May

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $896 From $979, Maintains Outperform Rating

MT Newswires Live
·
12 May

Trump Says He Will Cut Drug Prices by 59%

Reuters
·
12 May

Regeneron Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
09 May

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-05-08

Reuters
·
08 May

TRADING DAY-Absent tariff clarity, nerves fray

Reuters
·
07 May

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-05-06

Reuters
·
07 May

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

Zacks
·
02 May

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
02 May

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’

Insider Monkey
·
02 May

Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences

Simply Wall St.
·
02 May

Regeneron Pharma Is Maintained at Buy by Guggenheim

Dow Jones
·
01 May

Regeneron price target lowered to $940 from $975 at Truist

TipRanks
·
01 May

Regeneron to Highlight Advances at Asco With Phase 3 Adjuvant Libtayo® (Cemiplimab) Cscc Updates and Promising Early Blood Cancer Data With Linvoseltamab Combination

THOMSON REUTERS
·
01 May